First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study.
Sandra P D' AngeloCeleste LebbéLaurent MortierAndrew S BrohlNicola FazioJean-Jacques GrobNatalie PrinziGlenn J HannaJessica C HasselFelix KieckerSara GeorgesBarbara Ellers-LenzParantu ShahGülseren GüzelPaul T NghiemPublished in: Journal for immunotherapy of cancer (2022)
In patients with mMCC, first-line treatment with avelumab led to responses in 40% and durable responses in 30%, and was associated with a low rate of grade 3/4 treatment-related adverse events.